A Prospective Study of Efficacy and Safety of Once-Daily Saquinavir/Ritonavir plus Two Nucleoside Reverse Transcriptase Inhibitors in Treatment-Naive Thai Patients

Yeni P.G. , Hammer S.M. , Hirsch M.S. , Saag M.S. , Schechter M. , Carpenter C.C. , Fischl M.A. , Gatell J.M. , Gazzard B.G. , Jacobsen D.M. , Katzenstein D.A. , Montaner J.S. , Richman D.D. , Schooley R.T. , Thompson M.A. , Vella S. , & Volberding P.A. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 2004; 292: 251–265.

Pozniak A. , Gazzard B. , Anderson J. , Babiker A. , Churchill D. , Collins S. , Fisher M. , Johnson M. , Khoo S. , Leen C. , Loveday C. , Moyle G. , Nelson M. , Peter B. , Phillips A. , Pillay D. , Wilkins E. , Williams I. , & Youle M. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Medicine 2003; 4 (Suppl 1): 1–41.

World Health Organization. Scaling Up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach. 2003Revision. 2004. Geneva: World Health Organization.

Cardiello P.G. , Monhaphol T. , Mahanontharit A. , van Heeswijk R.P. , Burger D. , Hill A. , Ruxrungtham K. , Lange J.M. , Cooper D.A. , & Phanuphak P. Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjects. Journal of Acquired Immune Deficiency Syndromes 2003; 32: 375–379.

Kurowski M. , Sternfeld T. , Sawyer A. , Hill A. , & Mocklinghoff C. Pharmacokinetic and tolerability profile of twice-daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers. HIV Medicine 2003; 4: 94–100.

Hijazi Y. , Riek M. , Gaudeul–Erhart E. , & Grange S. Saquinavir 500mg tablet, a new formulation, has similar bioavailability to invirase 200mg capsule for healthy volunteers at 1000/100mg BID dosing with ritonavir. 2nd IAS Conference on HIV Pathogenesis and Treatment. 12–16 July 2003, Paris, France. Abstract 534.

Dragsted U.B. , Gerstoft J. , Pedersen C. , Peters B. , Duran A. , Obel N. , Castagna A. , Cahn P. , Clumeck N. , Bruun J.N. , Benetucci J. , Hill A. , Cassetti I. , Vernazza P. , Youle M. , Fox Z. , & Lundgren J.D. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. The Journal of Infectious Diseases 2003; 188: 635–642.

Youle M. , Gerstoft J. , Fox Z. , Losso M. , Jayaweera D. , Rieger A. , Bruun J.N. , Castagna A. , Walmsley S. , Hill A. , Dragsted U.B. , Lundgren J.D. , for the MaxCmin2 trial group. The final 48 week analysis of a phase IV, randomised, open-label, multicenter trial to evaluate safety and efficacy of lopinavir/ritonavir (400/100mg BID) versus saquinavir/ritonavir (1000/100 mg BID): the MaxCmin2 trial. 9th European AIDS Conference. 25–29 October 2003, Warsaw, Poland. Abstract F11/3.

Montaner J.S. , Saag M.S. , Barylski C. , & Siemon-Hryczyk P. Focus Study: Saquinavir QD regimen versus efavirenz QD regimen week 48 analysis in HIV–infected patients. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. 27–30 September 2002, San Diego, CA, USA. Abstract H-167.

Autar R.S. , Ananworanich J. , Apateerapong W. , Sankote J. , Hill A. , Hirschel B. , Cooper D. , Lange J. , Phanuphak P. , Ruxrungtham K. , & Burger D. Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily. The Journal of Antimicrobial Chemotherapy 2004; 54: 785–790.

Cardiello P.G. , van Heeswijk R.P. , Hassink E.A. , Srasuebkul P. , Mahanontharit A. , Samor T.M. , Worarien W. , Beijnen J.H. , Hoetelmans R.M. , Ruxrungtham K. , Cooper D.A. , Lange J.M. , & Phanuphak P. Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study. Journal of Acquired Immune Deficiency Syndromes 2002; 29: 464–470.

Kilby J.M. , Sfakianos G. , Gizzi N. , Siemon-Hryczyk P. , Ehrensing E. , Oo C. , Buss N. , & Saag M.S. Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults. The Journal of Antimicrobial Chemotherapy 2000; 44: 2672–2678.

Boffito M. , Dickinson L. , Hill A. , Back D. , Moyle G. , Nelson M. , Higgs C. , Fletcher C. , Mandalia S. , Gazzard B. , & Pozniak A. Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen. Antiviral Therapy 2004; 9: 423–429.

Gieschke R. , Fotteler B. , Buss N. , & Steimer J.L. Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients. Clinical Pharmacokinetics 1999; 37: 75–86.

Ford J. , Boffito M. , Wildfire A. , Hill A. , Back D. , Khoo S. , Nelson M. , Moyle G. , Gazzard B. , & Pozniak A. Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients. Antimicrobial Agents and Chemotherapy 2004; 48: 2388–2393.

Ananworanich J. , Siangphoe U. , Mahanontharit A. , Hill A. , Hirschel B. , & Ruxrungtham K. Saquinavir trough concentration before and after switching NRTI to tenofovir in patients treated with once-daily saquinavir hard gel capsule/ritonavir 1600 mg/100 mg. Antiviral Therapy 2004; 9: 1035–1036.

Zong J. , Chittick G. , Blum M.R. , Hill D. , Begley J. , Adda N. , Shah J. , & Kearney B.P. Pharmacokinetic assessment of tenofovir DF (TDF) and ritonavir (RTV)-boosted saquinavir (SQV/r) in healthy subjects. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. 30 October–2 November 2004, Washington, DC, USA. Abstract A444.

Boffito M. , D'Aviolo A. , Di Perri G. , Sciandra M. , Bonara S. , Back D. , Hill A. , Moyle G. , Nelson M. , Higgs C. , Tomkins J. , Gazzard B. , & Pozniak A. Repeated pharmacokinetics of tenofovir disoproxil fumarate (TDF) in HIV-infected adults receiving saquinavir (SQV) hard gel/ritonavir (RTV) 1000/100 mg BID. 5th International Workshop on Clinical Pharmacology of HIV Therapy. 1–3 April 2004, Rome, Italy. Abstract 4.19.

Gallant J.E. , Staszewski S. , Pozniak A.L. , DeJesus E. , Suleiman J.M. , Miller M.D. , Coakley D.F. , Lu B. , Toole J.J. , & Cheng A.K. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292: 191–201.

Saag M.S. , Cahn P. , Raffi F. , Wolff M. , Pearce D. , Molina J.M. , Powderly W. , Shaw A.L. , Mondou E. , Hinkle J. , Borroto-Esoda K. , Quinn J.B. , Barry D.W. , & Rousseau F. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. JAMA 2004; 292: 180–189.

Gathe J.C. Jr. , Ive P. , Wood R. , Schurmann D. , Bellos N.C. , DeJesus E. , Gladysz A. , Garris C. , & Yeo J. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. Aids 2004; 18: 1529–1537.

Walmsley S. , Bernstein B. , King M. , Arribas J. , Beall G. , Ruane P. , Johnson M. , Johnson D. , Lalonde R. , Japour A. , Brun S. , & Sun E. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. The New England Journal of Medicine 2002; 346: 2039–2046.

Ungsedhapand C. , Kroon E.D. , Suwanagool S. , Ruxrungtham K. , Yimsuan N. , Sonjai A. , Ubolyam S. , Buranapraditkun S. , Tiengrim S. , Pakker N. , Kunanusont C. , Lange J.M. , Cooper D.A. , & Phanuphak P. A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients. Journal of Acquired Immune Deficiency Syndromes 2001; 27: 116–123.

Bartlett J.A. , DeMasi R. , Quinn J. , Moxham C. , & Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. Aids 2001; 15: 1369–1377.

Schutz M. , Goodly J. , Chen K. , & Montaner J. Lack of correlation between saquinavir trough levels and adverse events or clinical outcome in saquinavir cohort of the FOCUS study. 41st Annual meeting, Infectious Diseases Society of America. 9–12 October 2003, San Diego, CA, USA. Abstract 654.

Justesen U. , Fox Z. , Pedersen C. , Cahn P. , Gerstoft J. , Clumeck N. , Duran A. , Peters B. , Obel N. , Castagna A. , Dragsted U. , Lundgren J. , on behalf of the MaxCmin1 trial group. Pharmacokinetics from a 48-week randomised trial to evaluate safety and efficacy of indinavir/ritonavir 800/100 mg versus saquinavir/ritonavir 1000/100 mg. The MaxCmin1 trial – PK substudy. 9th European AIDS Conference. 25–29 October 2003, Warsaw, Poland. Abstract F2/5.

van Heeswijk R.P. , Cohen Stuart J.W. , Burger D.M. , Beijnen J.H. , Borleffs J.C. , & Hoetelmans R.M. Long-term suppression of viral replication despite low plasma saquinavir concentrations in the CHEESE Study. British Journal of Clinical Pharmacology 2002; 53: 211–212.

Veldkamp A.I. , van Heeswijk R.P. , Mulder J.W. , Meenhorst P.L. , Schreij G. , van der Geest S. , Lange J.M. , Beijnen J.H. , & Hoetelmans R.M. Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals. Journal of Acquired Immune Deficiency Syndromes 2001; 27: 344–349.

Yeh V. , Barros C.P. , & Easterbrook P. Virologic response to a once daily lopinavir/ritonavir (LPV/r) based regimen in ARV-naive patients is not associated with trough lopinavir concentrations or baseline HIV RNA and CD4 count. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. 30 October–2 November 2004, Washington, DC, USA. Abstract H-570-363.